Marie-Claire Wagle

Sumitomo Dainippon Pharma (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

12h-index1.4kcitations83works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

PI3K/AKT/mTOR signaling in cancer(22), Melanoma and MAPK Pathways(22), HER2/EGFR in Cancer Research(21), Lung Cancer Treatments and Mutations(20), Cancer Immunotherapy and Biomarkers(13)

Publications83 total

10007-ACT-2 FIRST IN HUMAN STUDY OF DSP-0390, AN ORAL EMOPAMIL BINDING PROTEIN (EBP) INHIBITOR, IN RECURRENT HIGH-GRADE GLIOMA (HGG): PRELIMINARY RESULTS
Neuro-Oncology Advances·2023Open Access
CTNI-67. FIRST IN HUMAN STUDY OF DSP-0390, AN ORAL EMOPAMIL BINDING PROTEIN (EBP) INHIBITOR, IN RECURRENT HIGH-GRADE GLIOMA (HGG): PRELIMINARY RESULTS
Neuro-Oncology·2023Open Access
Supplementary Fig 1 from Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer
2023Open Access
Supplementary Tables from Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer
2023Open Access
Data from Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer
2023Open Access
Supplementary Tables from Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer
2023Open Access
Data from Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer
2023Open Access
Supplementary Fig 1 from Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer
2023Open Access
Figure S2 from CBP/p300 Drives the Differentiation of Regulatory T Cells through Transcriptional and Non-Transcriptional Mechanisms
2023Open Access
Supplementary Figure 1 from Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
2023Open Access
Supplementary Figure 4 from Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
2023Open Access
Supplementary Figure 4 from Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
2023Open Access
Figure S4 from CBP/p300 Drives the Differentiation of Regulatory T Cells through Transcriptional and Non-Transcriptional Mechanisms
2023Open Access
Supplementary Table 2 from Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
2023Open Access
Supplementary Table 3 from Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
2023Open Access
Supplementary Table 3 from Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
2023Open Access
Supplementary Table 5 from Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
2023Open Access
Supplementary Figure 2 from A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Table 6 from Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
2023Open Access
Figure S6 from CBP/p300 Drives the Differentiation of Regulatory T Cells through Transcriptional and Non-Transcriptional Mechanisms
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Mark R. Lackner(35), Garret M. Hampton(23), Yibing Yan(22), Matthew Wongchenko(21), Shih-Min A. Huang(18), Vanitha Ramakrishnan(18), Zineb Mounir(17), Sumati Murli(17), Deepak Sampath(17), Michelle Nannini(17), Josep Tabernero(17), Violeta Serra(16), Ludmila Prudkin(16), Maurizio Scaltriti(16), Marta Guzmán(16), Jenny Wu(16), Cristina Saura(16), Andrés Cervantes(16), José Baselga(16), Olga Rodríguez(15)